Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second...
Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 — Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief...
Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018– Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug...
Sutro Biopharma Announces $85.0 Million Initial Public Offering South San Francisco, California – September 26, 2018. Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated...
